Search

(GlobeNewswire) - Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedicas position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites [...]

Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica's position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple sites in EU, [...]

London: Oxford BioMedica PLC has issued the following press release: Oxford BioMedica PLC on Monday said that it has entered a sale and purchase agreement with TSGH SAS for the [...]

Oxford Biomedica signs agreement to acquire ABL Europe from Institut Merieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement with [...]

Oxford, UK: Oxford BioMedica plc has issued the following news release: Oxford Biomedica plc (LSE:OXB) ('Oxford Biomedica' or 'the Company'), a quality and innovation-led cell and gene therapy CDMO, and [...]

London: Oxford Biomedica PLC has issued the following press release: Oxford Biomedica PLC said Deputy Chair & Senior Independent Director Andrew Heath and a person closely associated with him, Eva [...]

Oxford: Oxford BioMedica has issued the following press release: Oxford BioMedica plc ('Oxford BioMedica' or 'the Company') (LSE: OXB), a leading gene and cell therapy company, announces that it has [...]

A British drug developer, Oxford BioMedica, said it was in discussions with an unidentified third party about a potential merger. The company makes gene-based treatments for cancer and neurological diseases, […]

M2 PHARMA-January 31, 2011-Oxford Biomedica to acquire manufacturing facility in Oxford(C)2011 M2 COMMUNICATIONS 31 January 2011 - UK-based gene therapy company Oxford BioMedica plc (LON: OXB) today announced it has [...]

Shares in Oxford BioMedica rose 19% to 10.25 pence on August 16, after the UK gene medicine firm rejected a takeover bid from US company GeneThera. The move was greeted [...]

Oxford BioMedica has entered into an agreement to acquire fellow Oxford, UK-based Oxxon Therapeutics, a privately-held biotechnology firm focused on the development of novel therapeutic vaccines for the treatment of [...]

Just a few weeks after revealing that it was in merger talks with an unnamed suitor, UK-based Oxford BioMedica said that negotiations had been called off, causing the firm's ramped [...]

BioWorld International Correspondent LONDON -- Oxford BioMedica plc is acquiring its fellow immunotherapy specialist Oxxon Therapeutics Ltd. in an all-paper deal that values Oxxon at 12 million [pounds sterling] (US$23.3 [...]

Oxford BioMedica plc, of Oxford, UK, agreed to acquire Oxxon Therapeutics Ltd, also of Oxford, in an all-share transaction valued at about 16 million [pounds sterling] (US$30.9 million). The deal [...]

* Oxford BioMedica plc, of Oxford, terminated the merger talks that were disclosed on Jan. 19. The company's stock price fell 5 pence to 19.5 pence on 5.3 million shares [...]

* Oxford BioMedica plc, of Oxford, UK, said it is at the early stage of merger discussions that might lead to an offer for the company. Oxford focuses on gene [...]